Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Aβ1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/ Hu APPswe PS1dE9 mouse model of Alzheimer's disease

Journal of Gene Medicine

Volumn 9, Issue 2, 2007, Pages 88-98

  Kim, Hong Duck ^a   Tahara, Kazuki ^a   Maxwell, J Adam ^a   Lalonde, Robert ^b   Fukuiwa, Tatsuya ^c   Fujihashi, Kohtaro ^c   Van Kampen, Kent R ^d   Kong, Fan Kun ^d   Tang, De Chu C ^d   Fukuchi, Ken Ichiro ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITÉ DE ROUEN   (France)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d Vaxin Incorporated   (United States)

Author keywords

Amyloid; DNA vaccine; Inflammation

Indexed keywords

ADENOVIRUS VECTOR; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-6]; IMMUNOGLOBULIN G1; INTERLEUKIN 10; PSEUDOMONAS EXOTOXIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INOCULATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEPTOR BINDING; TANDEM REPEAT; TH1 CELL; TH2 CELL; UPREGULATION;

ADENOVIRIDAE; ADMINISTRATION, INTRANASAL; ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; GENETIC VECTORS; IMMUNOGLOBULIN G; INTERLEUKIN-10; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; TANDEM REPEAT SEQUENCES; TH2 CELLS; UP-REGULATION; VACCINES, DNA;

ADENOVIRIDAE; MUS; PSEUDOMONAS;

EID: 33947385878     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.993     Document Type: Article

References (74)

1. Senechal Y. Larmet Y, Dev KK. Unraveling in vivo functions of mayloid precursor protein: insights from knockout and knockdown studies. Neurodegener Dis 2006; 3: 134-147.
2. Zheng H, Koo EH. The amyloid precursor protein: beyond amyloid. Mol Neurodegener 2006; 1: 5.
3. Caille I, Allinquant B, Dupont E, et al. Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone. Development 2004; 131: 2173-2181.
4. Kamal A, Mena-Queralt A, LeBlanc JF, et al. Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature 2001; 414: 643-648.
5. Inestrosa NC, Carpa W, Varela-Nallar L. Copper brain homeostasis: Role of amyloid precursor protein and prion protein. IUBMB Life 2005; 57: 645-650.
6. Guenette S, Chang Y, Hiesberger T, et al. Essential role for the FE65 amyloid precursor protein-interacting proteins in brain development. EMBO J 2006; 25: 420-431.
7. Oh SY, Ellenstein A, Chen CD, et al. Amyloid precursor protein interacts with notch receptors. J Neurosci Res 2005; 82: 32-42.
8. Selkoe, DJ. Alzheimer's disease is a synaptic failure. Science 2002; 298: 789-791.
9. Stokin GB, Lillo C, Falzone TL, et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimees disease. Science 2005; 307: 1282-1288.
10. Tanzi RE. The synaptic Abeta hypothesis of Alzheimer disease. Nat Neurosci 2005; 8: 977-979.
11. Hardy J. Amyloid double trouble. Nat Gener 2006; 38: 11-12.
12. Games D, Adams D, Alessandrini R, et al. Alzheimer type neuropathology in transgenic mice overexpressing V717F beta amyloid precursor protein. Nature 1995; 373: 523-527.
13. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits Abets elevation, and amyloid plaques in trnsgenic mice. Science 1996: 274: 99-102.
14. Janus C, Paerson J, McLaurin J, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000: 408: 979-982.
15. Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an appeal model of Alzheimer's disease Nature 2000; 408: 982-985.
16. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-177.
17. Orgogozo JM, Gilman S, Darugues M, et al. Subacute meningoencephalitis in a subset of patients with AD after Abet42 immunization. Neurology 2003; 61: 46-54.
18. Ferrer I, Boada, RM, Sanchez Guerra ML, et al. Neuropathology and pathogenesis of encephalitis following amyloid-beta immmunization in Alzheimer's disease. Brain Pathol 2004; 14: 11-20.
19. Nicoll JA. Wilkinson D, Holmes C, et al. Neuropathology of human Alheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9: 448-452.
20. Brad F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6: 916-919.
21. Gelinas DS, DaSilva K, Ferili D. et al. Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci USA 2004; 101: 14657-14662.
22. Goni F, Sigurdsson EM. New directions towards safer and effective vaccines for Alsheimer's disease. Curr Opin Mol Ther 2005; 7: 17-23.
23. Monsonego A, Weiner HL. Immunotherapentic approaches to Alzheimer's disease Science 2003; 302: 834-838.
24. Schenk D, Hagen M, Seubert P. Current progress in beta-amyloid immunotherapy. Curr Opin Immunol 2004; 16: 599-606.
25. Winsniewski T, Frangione B. Immunological and anti-chaperone therapeutic approaches for Alzheimer disease, Brain Pathol 2005; 15: 72-77.
26. Boyer JL, Kobinger G, Wilson JM, Crystal RG. Adenovirus-based genetic vaccines for biodefense. Hum Gene Ther 2005; 16: 157-168.
27. Liu M, Acres B, Balloul JM, et al. Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci U S A 2004; 101: 14567-14571.
28. Ghochikyan A. Vasilevko V, Petrishina I, et al. Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid interleukin-4 minigene. Eur J Immunol 2003; 33: 3232-3241.
29. Qu B, Rosenberg RN, Li L, et al. Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. Arch Neurol 2004: 61: 1859-1864.
30. Cribbs DH, Ghochikyan A, Vasilevko V, et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immumol 2003; 15: 505-514.
31. McLaurin J, Cecal R, Kierstead ME, et al. Therapeutically effective antibodies against mayloid-beta peptide target amyloid-beta residues 4-10 and inhibic cytotoxicity and fibrillogenesis. Nat Med 2002; 8: 1263-1269.
32. Town T. Tan J, Sansone N, et al. Characterization of murine immunoglobulin G antibodies against human amyloid-beta1-42. Neurosci Lett 2001; 307: 101-104.
33. Kim HD, Maxwell JA, Kong FK, et al. Induction of anti-inflammatory immune response by an adenovirus vector encoding 11 tandem repeats of Abeta1-6: toward safer and effective vaccines against Alzheimer's disease. Biochem Biophys Res Commun 2005; 336: 84-92.
34. Lee, CT, Wu S, Ciernik IF, et al. Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor. Hum Gene Ther 1997; 8: 187-193.
35. Jankowsky JL, Fadale DJ, Anderson J, et al. Mutant presenilins spicecifically elevate the levels of the 42 residue beta-amyloid peptide in vwo: evidence for augmentation of a 42-spectfic gamma secontace. Hum Mol Genet 2004; 13: 159-170.
36. Dahlgren KN, Manelli AM, Stine WB Jr, et al. Oligomeric and fibrillar species of amyloid-beta peptides diffentiatially affect neuronal viability. J Biol Chem 2002; 277: 32046-32053.
37. Fukuchi K, Pharn D, Hart M, et al. Amyloid-beta protein deposition in skeletal muscle of transgenic mice: possible model of inclusion body myopathy. Am J Pathol 1998; 153: 1687-1693.
38. Li L, Cao D, Garber DW, et al. Association of aortic atherosclerosis with cerebral beta-amyloidosis and learing deficits in a mouse model of Alzheimer's disease. Am J Pathol 2003; 163: 2155-2164.
39. Karaoka K, McGhee JR, Kobayashi R, et al. Nasal Flt3 ligand cDNA elicits CDllc+CD8+ dendritic cells for enhanced mucosal immunity. J Immunol 2004; 172: 3612-3619.
40. Agadjanyan MG, Ghochikyan A, Penrushina I, et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta amyloid and promiscuous T cell epitope pan HLA DR-binding pepride. J Immonol 2005; 174: 1580-1586.
41. Majer M, Seabrook TJ, Lamere CA, Modulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E coli enterotoxin LT(R192G). Vaccine 2005; 23: 5149-5159.
42. Kim HD, Kong FK, Cao Y, et al. Immunization of Alzheimer model mice with adenovirus vectors encoding amyloid beta-protein old GM-CSF reduces amyloid load in the brain Neurosci Lett 2004; 370: 218-223.
43. Bard F, Barbour R, Cannon C, et al. Epitope and isotype specificities of antibodies in beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A 2003; 100: 2023-2028.
44. Chauhan NB, Siegel GJ. Efficacy of anti-Abeta antibody isotypes used for intracebroventricular immunization in TgCRND8. Neurosci Lett 2005; 375: 143-147.
45. Santosuosso M, McCormick S, Xing Z. Adenoviral vectors for mucosal vaccination against infectious diseases. Virol Immunol 2005; 18: 283-291.
46. Titsis N, Ertl HC. Adenoviruses as vaccine vectors. Mol Ther 2004; 10: 616-629.
47. Bruna-Romero O, Rocha CD, Tsuji M, Gazzinelli RT. Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoire protein of Plasmodium lacking the GPI-anchoring motif. Vaccine 2004; 22: 3575-3584.
48. Liu Y, Xia D, Li F, et al. Intrammoral administration of immature dendritic cells following the adenovirus vertor encoding CD40 ligand elicits significant regression of established mycloma. Cancer Gene Ther 2005; 12: 122-132.
49. Meng WS, Butterfield LH, Ribas A, et al. alpha-Fetoprotein-specific specific tumor immunity induced by plasmid prime adenovirus boost genetic vaccination. Cancer Res 200l; 61: 8782-8786.
50. Rollier C, Vershoor EJ. Paranhos-Baccala G, et al. Modulation of vaccine indiced responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting. J Infect Dis 2005; 192: 920-929.
51. Rea D, Schagen FH, Hoeben RC, et al. Adenoviruses acrivate human dendritic cells without polarization toward a T-helper type 1-indwirig subset. J Virol 1999; 73: 10245-10253.
52. Xiang ZQ, Pasquini S, Ertl HC. Induction of genital immunity by DNA priming and intranasal booster immunization with a replication defective adenoviral recombinant. J Immunol 1999; 162: 6716-6723.
53. Corini S, Albanesi C, la Sala A, et al. Regulatory activity of autoocrine IL-10 an dendritic cell functions. J Immunol 2001; 166: 4312-4318.
54. Daly LM, Johnson PA, Donnelly G, et al. Innate IL-10 promotes the induction of Th2 responses with plasmid DNA expressing HPV gp120. Vaccine 2005; 23: 963-974.
55. Huang LY, Reis e Sousa, Itoh Y, et al, IL-12 induction by a TH1-inducing adjuvant in vivo: dendritic cell subsets and regulation by IL-10. J Immunol 2001; 167: 1423-1430.
56. Xu-Amano J, Kiyono H, Jackson RJ, et al. Helper T cell subsets for immonoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J Exp Med 1993; 178: 1309-1320.
57. Xu-Amano J, Jackson RJ, Fujihashi K, et al. Helper Thl and Th2 cell responses following mucosal or systemic immunization with cholera toxin. Vaccine 1994; 12: 903-911.
58. Yamamoto S, Kiyono, H, Yamamotp M, et al. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc Natl Acad Sci USA 1997; 94: 5267-5272.
59. Nakagawa I, Takahashi I, Kiyono H, et al. Oral immunization with the B subunit of he heat-labile enterotoxin of Escherichia coli induces early TH1 and lare Th2 cytokine expression in Peyer's patches. J Infect Dis 1996; 173: 1428-1436.
60. VanCott JL, Staats HF, Pascual DW, et al. Regulation of mucosal and systemic antibody responses by T helper cell subsets, macrophages, and derived cyrokines following oral immunization with live recombinant Salmonella. J Immunol 1996; 156: 1504-1514.
61. Van Ginkel FW, McGhee JR, Liu C, et al. Adenoviral gene delivery elicits distinct pulmonary-associated T helper cell responses in the vector and to its transgene. J Immunol 1997; 159: 685-693.
62. Haddad D, Liljeqvist S, Stahl S, et al. Differential induction of immunoglobulin G subclasses by immunization with DNA vectors containing or lacking a signal sequence. Immunol Lett 1998; 61: 201-204.
63. Lewis PJ, van Drunen Litrel-van den Hurk, Babiuk LA. Alterring the cellular location of an antigen expressed by a DNA-based vaccine modulates the immune response. J Virol 1999; 73: 10214-10223.
64. McGuirk P, McCann C, Mills KH. Pathogen spescific T regulatory 1 cells indured in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J Exp Mol 2002; 195: 221-231.
65. Freakel D, Huang Z, Maron R, et al. Neuroprotection by IL-10-producing MOG CD4+ T cells Following ischemic stroke. J Neurol Sci 2005; 233: 125-132.
66. Gonnella PA, Waldner HP, Kodali D, Weiner HL. Induction of low dose oral tolerance in IL-10 deficient mice with experimental autoimmune encephalomyelitis. J Autoimmunol 2004; 23: 193-200.
67. Furlan R, Brambilla E, Sanvito F, et al. Vaccination with amyloid-beta peptide induces autoimunne encephalomyelitis in C57/BL6 mice. Brain 2003; 126: 285-291.
68. Lee EB, Leng LZ, Lee VM. Trojanowski JQ. Meningionencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis FEBS Lett 2005; 579: 2564-2568.
69. Mosliash E, Hansen L. Adame A. et al. Abeta vaccination effects an plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005; 64: 129-131.
70. Pfeifer M, Boncristiano S, Bondolfi L, et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002; 298: 1379.
71. Racke MM, Boone LI, Hepbum DL, et al. Exacerbation of cerebral amyloid angiopathy-associated microchemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent rat antibody recognition of deposited forms of amyloid beta. J Neurosci 2005 25: 629-636.
72. Wilcock DM, Rojiani A, Rosenthal A, et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 2004; 1: 24.
73. Codita A, Winblad B, Mohammed AH. Of mice and men: more neurobiology to dementia, Curr Opin Psychiatry 2006; 19: 555-563.
74. Gandy S, Walker L. Toward modeling hemorrhagic and encephalitic complications of Alzheimer amyloid-beta vaccination in nonhuman primates. Curr Clim Immunol 2004; 16: 607-615.